New Non-Drowsy Claritin 12-Hour Out In Market
An over-the-counter drug to treat symptoms such as itchy, watery eyes, sneezing, and runny nose
Schering-Plough has introduced Claritin 12-Hour, the 12-hour allergy medicine found in the allergy aisle. New Claritin 12-Hour lasts all day and provides effective, non-drowsy relief from the worst indoor and outdoor allergy symptoms. The product is available for adults and children ages six and up.
John O'Mullane, group vice president of research and development at Schering-Plough Consumer Health Care, said: New Claritin 12-Hour offers the proven allergy relief people have relied on for years, with the added flexibility for people who want more control of their treatment.”
The company claims, Claritin 12-Hour, which comes as RediTabs tablets, dissolves quickly without water. It is also convenient for moms looking to give their kids all day allergy relief, while allowing the flexibility to re-dose at night, if needed.
New Claritin 12-Hour is available without a prescription and treats allergy symptoms such as itchy, watery eyes, sneezing, and runny nose without drowsiness.
Related Insight
Suppliers Directory
Lomapharm - Your Competent Partner for Solid and Liquid Pharmaceuticals
Lomapharm®: Pharmaceutical competence with a long tradition.
Suppliers
Promega – Solutions To Develop Better Drugs Faster
Promega is a renowned innovator of reagents and consumables for the life sciences and drug discovery industries, with a solid reputation for expert technical support. With over 2,000 catalogue products, a growing portfolio of custom offerings and OEM solutions, Promega enables scientists and businesses alike to advance their research and their competitiveness.
Contract Research & Services > Contract Research > Suppliers
ELPRO - High Quality Temperature and Humidity Dataloggers
ELPRO, The Datalogging Company, is a leading manufacturer of high quality temperature, humidity and other process variables Dataloggers, providing recording and monitoring solutions while observing regulatory compliances (GMP/GLP/FDA 21CFR11).
Suppliers
C3 Research Associates - Clinical Research Development and Management Group
C3 Research Associates is a quality-focused clinical research development and management group supporting innovative biotechnology, medical device and pharmaceutical organizations, stewarding therapeutics from preclinical through phase IV drug development and successful market life cycle.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Insights from Close Loop Marketing Implementation
Published by Kinapse
White Papers
Evidence Investigator
Published by Randox
White Papers
Tips & Tricks - GPC/SEC: How to Validate a GPC/SEC System
Published by Polymer Standards Service
White Papers
HPLC Analysis of Fluorescently labelled N-Glycans
Published by Ludger
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.